No Data
Are Investors Undervaluing Hubei Jumpcan Pharmaceutical Co., Ltd. (SHSE:600566) By 47%?
Hubei Jumpcan Pharmaceutical Gets China Approval for Antibiotics
Hubei Jumpcan Pharmaceutical (600566.SH): Subsidiary obtained the Pharmaceutical registration certificate.
On December 12, Gelonghui reported that Hubei Jumpcan Pharmaceutical (600566.SH) announced that its wholly-owned subsidiary, Hubei Jumpcan Pharmaceutical Group Co., Ltd., and Shaanxi Dongke Pharmaceutical Co., Ltd. received the pediatric Faropenem sodium granule "Drug Registration Certificate" and the injectable Cefoperazone Sodium "Drug Registration Certificate" approved by the National Medical Products Administration. The registration of pediatric Faropenem sodium granules is classified as Chemical Drug Class 4, and it was reviewed and approved in accordance with the technical requirements consistent with the quality and efficacy of the reference preparation. Once approved, it is regarded as having passed the consistency evaluation of the quality and efficacy of generic drugs, mainly used for treating pediatric infectious diseases caused by bacteria sensitive to Faropenem.
Here's Why We Think Hubei Jumpcan Pharmaceutical (SHSE:600566) Might Deserve Your Attention Today
Jumpcan Pharmaceutical Unit's Two Drugs Added to National Insurance Catalog
hubei jumpcan pharmaceutical (600566.SH) subsidiary products include children's chiqiaoqingtang syrup and venlafaxine hydrochloride suspension powder entering the national medical insurance catalog
On December 1, Gelonghui reported that hubei jumpcan pharmaceutical (600566.SH) announced that according to the notice issued by the National Medical Insurance Administration and the Ministry of Human Resources and Social Security regarding the 'National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2024)', the products of its wholly-owned subsidiary, hubei jumpcan pharmaceutical group co., ltd., namely pediatric chichiao clearing heat syrup and fexofenadine hydrochloride dry suspension, have been included in the 'National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2024)' (hereinafter referred to as the 'National Medical Insurance Catalogue') for the first time through negotiations.
Hubei Jumpcan Pharmaceutical Co., Ltd.'s (SHSE:600566) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
No Data
